ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients

Marchetti, Oscar; Lamoth, Frédéric; Mikulska, Małgorzata; Viscoli, Claudio; Verweij, Paul E.; Bretagne, Stéphane

doi:10.1038/bmt.2011.178

Cited by 237 publications

(195 citation statements)

References 64 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…gokhanmetan@gmail.com; gokhanmetan@hacettepe.edu.tr 1 Aspergillus-lateral-flow device (Aspergillus-LFD) has been recently developed by Chris Thornton from the University of Exeter, UK. This test is an immuno-chromatographic assay which is based on the detection of Aspergillus antigen released during the hyphal invasion by a monoclonal IgG antibody JF5.…”

Section: And Gökhan Metanmentioning

confidence: 99%

“…BDG levels in sera were assayed using the Fungitell kit (Associates of Cape Cod, East Falmouth, MA, USA) according to manufacturer's specifications. The cut-off was 80 pg/ml [1].…”

Section: Sample Collection and Biomarker Testingmentioning

confidence: 99%

“…The results were expressed in terms of the GM index. Cutoff level of 0.7 were used to define the positivity of the test [1]. Screening tests were started at the day of an absolute neutrophil count of \500/mm 3 until recovery of neutropenia or diagnosis of IFDs.…”

Section: Sample Collection and Biomarker Testingmentioning

confidence: 99%

“…Severe hypoxemia or thrombocytopenia usually limit the deep tissue sampling for culture which is the golden standard for the diagnosis. The well characterized serological tools such as galactomannan (GM) and 1,3-beta-D-glucan (BDG) need spesific laboratory equipment and experienced staff [1].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Performance of Galactomannan Antigen, Beta-d-Glucan, and Aspergillus-Lateral-Flow Device for the Diagnosis of Invasive Aspergillosis

Metan

Keklik

Dinç

et al. 2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Aspergillus lateral-flow device (LFD) was recently introduced as a practical tool for the diagnosis of invasive aspergillosis (IA). We investigated the performance of Aspergillus-LFD as a point-of-care test for the diagnosis of IA. Serum samples were collected twice weekly from patients who received intensive chemotherapy for acute leukemia, or recepients of allogeneic stem cell transplantation. Aspergillus galactomannan (GM) antigen,

show abstract

Section: And Gökhan Metanmentioning

confidence: 99%

“…BDG levels in sera were assayed using the Fungitell kit (Associates of Cape Cod, East Falmouth, MA, USA) according to manufacturer's specifications. The cut-off was 80 pg/ml [1].…”

Section: Sample Collection and Biomarker Testingmentioning

confidence: 99%

Section: Sample Collection and Biomarker Testingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Performance of Galactomannan Antigen, Beta-d-Glucan, and Aspergillus-Lateral-Flow Device for the Diagnosis of Invasive Aspergillosis

Metan

Keklik

Dinç

et al. 2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…Notably, current ECIL guidelines suggest the use of monitoring for galactomannan in neutropenic patients who have a relatively high a priori probability (5-10%) of developing IA. 35 Other authors have recently used an animal model to explore the possible influence of antifungal drugs on both galactomannan and quantitative PCR-based assays. It was found that the use of posaconazole in either prophylaxis or treatment may reduce the value of a negative PCR result in the early phase of aspergillosis, resulting in the need for daily PCR-based determinations for the first week.…”

confidence: 99%

The management of febrile neutropenia in the posaconazole era: a new challenge?

Pagano

Caira²,

Cuenca‐Estrella³

2012

Haematologica

View full text Add to dashboard Cite

Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics

et al. 2020

View full text Add to dashboard Cite

Annually, ~50,000 patients undergo hematopoietic stem cell transplantation (HCT) worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a curative option for a wide range of hematologic malignancies, and advances in transplantation medicine have resulted in an increase in HCT survivors. It is anticipated that the number of HCT survivors will more than double from 242,000 in 2020 to ~500,000 in 2030. Survivors of HCT are at an increased risk of developing late complications due to exposure to chemotherapy and/or radiation in the pre‐, peri‐, and post‐HCT phases and these cumulative exposures have the potential to damage normal tissue. This tissue damage leads to the early onset of chronic health conditions resulting in premature mortality in HCT survivors, who have a 15‐year cumulative incidence of severe or life‐threatening chronic health conditions exceeding 40%. Due to the significant burden of morbidity in HCT survivors and the delay in the development of long‐term complications, this delicate patient population requires life‐long monitoring due to the risk for neuropsychological, cardiac, pulmonary, renal, hepatic, ocular, skeletal, cardiac, endocrine, fertility, and sexual health complications, as well as secondary neoplasms. This review will focus on recent advances in screening, monitoring, and therapeutics for late‐occurring or long‐term complications in HCT survivors.

show abstract

ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients

Cited by 237 publications

References 64 publications

Performance of Galactomannan Antigen, Beta-d-Glucan, and Aspergillus-Lateral-Flow Device for the Diagnosis of Invasive Aspergillosis

Performance of Galactomannan Antigen, Beta-d-Glucan, and Aspergillus-Lateral-Flow Device for the Diagnosis of Invasive Aspergillosis

The management of febrile neutropenia in the posaconazole era: a new challenge?

Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics

Contact Info

Product

Resources

About